Researchers at Memorial Sloan-Kettering Cancer Center (MSKCC) have reported both preclinical data and a case study of a patient treated under a compassionate use protocol indicating that the tropomyosin receptor kinase (TRK) fusion inhibitor larotrectinib (LOXO-101, Loxo Oncology Inc.) is effective in hematological malignancies as well as in solid tumors, where it is currently in late-stage clinical trials.